CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma

Gregory M. Hayes, Belinda Cairns, Zoia Levashova, Lawrence Chinn, Myra Perez, Jan Willem Theunissen, Sindy Liao-Chan, Abel Bermudez, Mark Flory, Karl J. Schweighofer, Edward H. van der Horst

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm represented by approximately 50 histological subtypes. Effective therapeutic intervention is lacking for recurrent, late stage and metastatic disease. CD39, a cell-surface ectonucleotidase, has previously been shown to be upregulated in hematological malignancies and various epithelial tumors, but not in STS. Here, we show by mass spectrometry and immunohistochemistry that CD39 is highly expressed in primary patient sarcoma samples. Moreover, CD39 nucleotidase activity is enhanced in fibrosarcoma compared with normal control cells. We demonstrate that an inhibitory monoclonal anti-CD39 antibody, abrogates CD39 enzymatic activity significantly and prolongs survival in a lethal metastatic patient-derived sarcoma model. Taken together, the data suggest CD39 is a novel therapeutic target for the treatment of STS.

Original languageEnglish (US)
Pages (from-to)1181-1188
Number of pages8
JournalAmerican Journal of Translational Research
Volume7
Issue number6
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Sarcoma
nucleotidase
Tissue
Antibodies
Tumors
Mass spectrometry
Therapeutics
Fibrosarcoma
Mesoderm
Hematologic Neoplasms
Anti-Idiotypic Antibodies
Mass Spectrometry
Neoplasms
Immunohistochemistry
Monoclonal Antibodies
Survival
ectoATPase

Keywords

  • CD39
  • Immunohistochemistry
  • In vivo efficacy
  • Mass spectrometry
  • Monoclonal antibody
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Clinical Biochemistry
  • Cancer Research

Cite this

Hayes, G. M., Cairns, B., Levashova, Z., Chinn, L., Perez, M., Theunissen, J. W., ... van der Horst, E. H. (2015). CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. American Journal of Translational Research, 7(6), 1181-1188.

CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. / Hayes, Gregory M.; Cairns, Belinda; Levashova, Zoia; Chinn, Lawrence; Perez, Myra; Theunissen, Jan Willem; Liao-Chan, Sindy; Bermudez, Abel; Flory, Mark; Schweighofer, Karl J.; van der Horst, Edward H.

In: American Journal of Translational Research, Vol. 7, No. 6, 01.01.2015, p. 1181-1188.

Research output: Contribution to journalArticle

Hayes, GM, Cairns, B, Levashova, Z, Chinn, L, Perez, M, Theunissen, JW, Liao-Chan, S, Bermudez, A, Flory, M, Schweighofer, KJ & van der Horst, EH 2015, 'CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma', American Journal of Translational Research, vol. 7, no. 6, pp. 1181-1188.
Hayes GM, Cairns B, Levashova Z, Chinn L, Perez M, Theunissen JW et al. CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. American Journal of Translational Research. 2015 Jan 1;7(6):1181-1188.
Hayes, Gregory M. ; Cairns, Belinda ; Levashova, Zoia ; Chinn, Lawrence ; Perez, Myra ; Theunissen, Jan Willem ; Liao-Chan, Sindy ; Bermudez, Abel ; Flory, Mark ; Schweighofer, Karl J. ; van der Horst, Edward H. / CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. In: American Journal of Translational Research. 2015 ; Vol. 7, No. 6. pp. 1181-1188.
@article{c854c607227647f4a920d6d11c747077,
title = "CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma",
abstract = "Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm represented by approximately 50 histological subtypes. Effective therapeutic intervention is lacking for recurrent, late stage and metastatic disease. CD39, a cell-surface ectonucleotidase, has previously been shown to be upregulated in hematological malignancies and various epithelial tumors, but not in STS. Here, we show by mass spectrometry and immunohistochemistry that CD39 is highly expressed in primary patient sarcoma samples. Moreover, CD39 nucleotidase activity is enhanced in fibrosarcoma compared with normal control cells. We demonstrate that an inhibitory monoclonal anti-CD39 antibody, abrogates CD39 enzymatic activity significantly and prolongs survival in a lethal metastatic patient-derived sarcoma model. Taken together, the data suggest CD39 is a novel therapeutic target for the treatment of STS.",
keywords = "CD39, Immunohistochemistry, In vivo efficacy, Mass spectrometry, Monoclonal antibody, Soft tissue sarcoma",
author = "Hayes, {Gregory M.} and Belinda Cairns and Zoia Levashova and Lawrence Chinn and Myra Perez and Theunissen, {Jan Willem} and Sindy Liao-Chan and Abel Bermudez and Mark Flory and Schweighofer, {Karl J.} and {van der Horst}, {Edward H.}",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "7",
pages = "1181--1188",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "6",

}

TY - JOUR

T1 - CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma

AU - Hayes, Gregory M.

AU - Cairns, Belinda

AU - Levashova, Zoia

AU - Chinn, Lawrence

AU - Perez, Myra

AU - Theunissen, Jan Willem

AU - Liao-Chan, Sindy

AU - Bermudez, Abel

AU - Flory, Mark

AU - Schweighofer, Karl J.

AU - van der Horst, Edward H.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm represented by approximately 50 histological subtypes. Effective therapeutic intervention is lacking for recurrent, late stage and metastatic disease. CD39, a cell-surface ectonucleotidase, has previously been shown to be upregulated in hematological malignancies and various epithelial tumors, but not in STS. Here, we show by mass spectrometry and immunohistochemistry that CD39 is highly expressed in primary patient sarcoma samples. Moreover, CD39 nucleotidase activity is enhanced in fibrosarcoma compared with normal control cells. We demonstrate that an inhibitory monoclonal anti-CD39 antibody, abrogates CD39 enzymatic activity significantly and prolongs survival in a lethal metastatic patient-derived sarcoma model. Taken together, the data suggest CD39 is a novel therapeutic target for the treatment of STS.

AB - Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm represented by approximately 50 histological subtypes. Effective therapeutic intervention is lacking for recurrent, late stage and metastatic disease. CD39, a cell-surface ectonucleotidase, has previously been shown to be upregulated in hematological malignancies and various epithelial tumors, but not in STS. Here, we show by mass spectrometry and immunohistochemistry that CD39 is highly expressed in primary patient sarcoma samples. Moreover, CD39 nucleotidase activity is enhanced in fibrosarcoma compared with normal control cells. We demonstrate that an inhibitory monoclonal anti-CD39 antibody, abrogates CD39 enzymatic activity significantly and prolongs survival in a lethal metastatic patient-derived sarcoma model. Taken together, the data suggest CD39 is a novel therapeutic target for the treatment of STS.

KW - CD39

KW - Immunohistochemistry

KW - In vivo efficacy

KW - Mass spectrometry

KW - Monoclonal antibody

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84939555315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939555315&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84939555315

VL - 7

SP - 1181

EP - 1188

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 6

ER -